Abstract:TP53 alteration in chronic lymphocytic leukemia indicates a high-risk disease that is usually refractory to chemotherapy. It may be caused by deletion of 17p involving the loss of TP53 gene, which occurs in low percentage of patients at diagnosis but can be acquired as the disease progresses. Since patients may harbor TP53 mutation without chromosome 17p deletion, consensus recommendations call for both cytogenetic and PCR mutation analysis of TP53 in chronic lymphocytic leukemia. We conducted a single-institution retrospective study to investigate the clinicopathologic features of chronic lymphocytic leukemia with TP53 alterations as well as the utility of different diagnostic modalities to identify p53 alterations. Forty percent of chronic lymphocytic leukemia patients with TP53 alterations demonstrated atypical lymphocytes with cleaved/irregularly shaped nuclei and/or large atypical lymphoid cells with abundant cytoplasm in the peripheral blood. Progression was also observed in lymph node and bone marrow samples (21% with Richter transformation; 33% with findings suggestive of "accelerated phase" of chronic lymphocytic leukemia including prominent proliferation centers and/or increased numbers of prolymphocytes). However, the presence of the morphologic features suggestive of "accelerated phase" had no effect on overall survival within the chronic lymphocytic leukemia group with TP53 abnormalities (p > 0.05). As previously reported by others, a subset of patients with TP53 alterations were only identified by either PCR mutation analysis (12%) or cytogenetic studies (14%). p53 immunostain positivity was only identified in approximately half of the patients with TP53 alterations identified by either method, and it failed to identify any additional patients with p53 abnormalities. In summary, chronic lymphocytic leukemia patients with TP53 alterations frequently show atypical morphologic features. Use of multiple modalities to identify p53 abnormalities is recommended to ensure optimal sensitivity and specificity.

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

TP53 Mutations Are Associated with Very Complex Karyotype and Suggest Poor Prognosis in Newly Diagnosed Myelodysplastic Syndrome Patients with Monosomal Karyotype.

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Clinical analysis on 15 acute myeloid leukemia patients with 11p15 abnormalities

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations

Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia

Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis

[Clinical Implications and Prognostic Value of TP53 Gene Mutation and Deletion in Patients with Myelodysplastic Syndromes].

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

What have we learned about TP53- mutated acute myeloid leukemia?

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment

Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%